HanchorBio Expands Global Pharma Engagement at BioJapan 2026
Company schedules over 15 partnering meetings to advance co-development opportunities for its FBDB™ pipeline in oncology and autoimmune diseases
[Taipei, Shanghai, San Francisco | October 9, 2026] – HanchorBio, Inc. (TWSE: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies, today announced its participation in BioJapan 2026 in Yokohama, Japan. The Company has scheduled more than 15 partnering meetings with regional and global pharmaceutical leaders to explore co-development and strategic collaboration opportunities across its proprietary Fc-based Designer Biologics (FBDB™) platform.
Japan remains a primary focus of HanchorBio’s international business development strategy. Following discussions initiated at BIO Asia–Taiwan earlier this year, several Japanese pharmaceutical companies have advanced HanchorBio’s assets into deeper evaluation stages.
“BioJapan provides a key forum to accelerate our momentum in Asia’s largest pharmaceutical market,” said Scott Liu, Ph.D., Chairman and CEO at HanchorBio. “As our programs mature, we are seeing increased global interest in both our clinical assets and our underlying FBDB™ platform to address high unmet needs in oncology and autoimmune diseases.”
Key Pipeline Highlights
HCB206: A novel bispecific fusion protein targeting CD20 and SIRPα, extending HanchorBio’s macrophage-directed strategy into B-cell-mediated autoimmune diseases to achieve deeper, more durable B-cell depletion. The asset is currently in the preclinical, IND-enabling stage.
HCB101: HanchorBio’s lead clinical-stage SIRPα-based innate immune checkpoint inhibitor, serving as the cornerstone of its oncology strategy.
HCB303: A first-in-class trispecific fusion protein biologic targeting SIRPα/CD47, PD-L1/PD-1, and TIGIT/PVR pathways. Designed to engage macrophages, T cells, and NK cells simultaneously, HCB303 recently received U.S. FDA Investigational New Drug (IND) clearance to begin Phase 1 trials. It is HanchorBio’s second trispecific fusion protein biologic to enter human clinical development.
HCB206: A novel bispecific fusion protein targeting CD20 and SIRPα, extending HanchorBio’s macrophage-directed strategy into B-cell-mediated autoimmune diseases to achieve deeper and more durable B-cell depletion. The asset is currently in the preclinical and IND-enabling stage.
Building Global Relationships Across the FBDB™ Platform
HanchorBio continues to advance global business development alongside the clinical and preclinical development of its pipeline. Through BioJapan and other international industry and scientific forums, the Company is expanding relationships with global pharmaceutical and biotechnology companies and exploring strategic collaborations that can support the global development of its programs.
As HCB101 advances in clinical development and HCB301, HCB303, HCB206 and other programs continue to progress, HanchorBio remains focused on building long-term global relationships that can maximize the development potential of its differentiated pipeline and FBDB™ platform.
About HanchorBio
HanchorBio (TWSE: 7827) is a global clinical-stage biotechnology company dedicated to developing transformative immunotherapies for patients with cancer and immune-mediated diseases.
Powered by its proprietary Fc-based Designer Biologics (FBDB™) platform, HanchorBio engineers multi-functional bi- and tri-specific fusion proteins that targetedly modulate innate and adaptive immune responses. Headquartered in Taipei with operational footprints in Shanghai and San Francisco, HanchorBio is committed to advancing its pipeline through global clinical development and strategic partnerships.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the development and clinical advancement of HanchorBio’s product candidates; the potential therapeutic characteristics and mechanisms of HCB101, HCB301, HCB303, HCB206 and other pipeline programs; the capabilities and potential of the FBDB™ platform; and the Company’s global business development, strategic collaboration and partnering activities. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those described. Statements regarding discussions with potential partners do not imply that any transaction or collaboration will be entered into or completed. FDA clearance of an IND permits clinical investigation to proceed but does not constitute approval of a product candidate or provide assurance regarding its safety, efficacy or successful development. HanchorBio undertakes no obligation to update forward-looking statements except as required by applicable law.
Investor & Media Contact:
Email: [email protected]
HanchorBio Business Development Contact:
Email: [email protected]
漢康生技參展BioJapan 2026 深化日本市場拓展並推進全球合作機會
逾15場一對一合作會談，推進FBDB™平台於腫瘤及自體免疫疾病領域的共同開發機會
【台北、上海、舊金山，2026年10月9日】－全球臨床階段生技公司漢康生技（TWSE：7827），致力於開發應用於腫瘤及免疫介導疾病的次世代免疫療法，宣布參加於日本橫濱舉行的BioJapan 2026，持續拓展日本及全球市場的策略合作與授權機會。
日本為全球重要的醫藥市場之一，也是漢康生技全球商務開發策略的重點市場之一。延續今年亞洲生技大展期間與多家日系藥廠的交流，漢康生技持續就旗下候選藥物與潛在合作夥伴進行後續洽談；部分合作討論已由初步接觸進一步推進至資產評估及更深入的交流，展現公司國際商務開發持續推進的動能。
此次BioJapan漢康生技團隊赴日參展，目前已安排逾15場一對一媒合會議，洽談對象涵蓋日本癌症領域領先藥廠、亞洲大型製藥企業及全球大型跨國藥廠。公司將藉此深化既有合作接觸，同時拓展潛在全球共同開發及策略合作機會。
漢康生技董事長暨執行長劉世高博士表示：「BioJapan是我們進一步加速日本市場及亞洲合作動能的重要平台。隨著旗下產品開發持續推進，我們看到全球藥廠對漢康臨床階段產品，以及FBDB™平台在腫瘤與自體免疫疾病高度未滿足醫療需求上的應用潛力，展現出更積極的合作興趣。」
漢康產品線持續獲全球藥廠關注 合作交流橫跨腫瘤與免疫介導疾病
隨著漢康生技與全球藥廠的交流逐步拓展至腫瘤及免疫介導疾病等多項產品，公司專有 FBDB™ 平台所建立的多元產品布局及跨疾病領域延伸潛力亦持續受到關注。
其中，HCB101 為漢康生技主要的 SIRPα 導向先天免疫檢查點候選藥物，目前持續推進臨床開發，並仍為公司全球開發策略的核心產品。近期 HCB303 與 HCB206 亦在與日本藥廠的交流中受到關注，進一步擴大公司旗下產品線的對外合作接觸。
隨著漢康生技產品線持續拓展，HCB206與HCB303近期亦成為公司與日本藥廠交流的重要候選資產，分別布局免疫介導疾病及腫瘤治療領域，展現FBDB™多功能融合蛋白平台跨疾病領域的延伸潛力。
HCB206為漢康生技以 FBDB™ 平台開發靶向CD20及SIRPα的雙特異性融合蛋白，將公司既有的巨噬細胞導向免疫策略由腫瘤進一步拓展至自體免疫疾病。HCB206鎖定與致病性B細胞相關的疾病生物學，透過CD20標靶與巨噬細胞導向的免疫機制，探索更深度且持久的B細胞清除策略，並持續推進相關臨床前與IND開發工作。
HCB303則為漢康生技自主研發、具First-in-Class潛力的三特異性融合蛋白生物藥，整合SIRPα/CD47、PD-L1/PD-1及TIGIT/PVR三條免疫路徑，旨在透過單一分子協同巨噬細胞、T 細胞與 NK 細胞免疫作用。HCB303更於日前獲美國食品藥物管理局（FDA）同意新藥臨床試驗申請（IND），得以推進第一期人體臨床試驗，為第二款漢康生技進入人體臨床試驗的三特異性融合蛋白生物藥。
從國際交流走向實質資產評估 持續擴大全球合作網絡
漢康生技持續同步推進全球商務開發與研發進程，透過國際生技大會、專業醫學會議及一對一商務媒合，深化與全球製藥及生技公司的合作交流。隨著 HCB101 臨床開發持續推進，以及 HCB301、HCB303、HCB206 等產品陸續取得進展，公司將持續以差異化候選藥物與 FBDB™ 平台為基礎，建立長期全球合作關係，以進一步發揮旗下產品線與平台的全球開發潛力。
關於漢康生技
漢康生技（TWSE：7827）是一家全球臨床階段生技公司
，致力於為癌症及免疫相關疾病患者開發具突破潛力的創新免疫療法。透過自主開發的Fc-based Designer Biologics（FBDB™）平台，漢康生技開發多功能雙特異性及三特異性融合蛋白，以精準調控先天性與適應性免疫反應。
漢康生技總部位於台北，並於上海及舊金山設有營運據點，持續透過全球臨床開發與策略合作推進旗下產品線。
前瞻性聲明
本新聞稿包含前瞻性聲明，包括有關漢康生技候選藥物之開發與臨床推進；HCB101、HCB301、HCB303、HCB206 及其他產品線項目的潛在治療特性與作用機制；FBDB™ 平台的能力與潛力；以及公司全球商務開發、策略合作與夥伴關係活動等相關陳述。
上述聲明係基於目前的預期與假設，並涉及可能導致實際結果與所述內容產生重大差異的風險與不確定性。關於與潛在合作夥伴進行討論的相關陳述，並不代表任何交易或合作一定會達成或完成。美國 FDA 同意 IND 僅表示相關臨床研究得以進行，並不構成對候選藥物的核准，亦不代表其安全性、有效性或後續開發成功具有任何保證。
除適用法律另有要求外，漢康生技不負有更新任何前瞻性聲明之義務。